JPWO2020163365A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020163365A5 JPWO2020163365A5 JP2021545400A JP2021545400A JPWO2020163365A5 JP WO2020163365 A5 JPWO2020163365 A5 JP WO2020163365A5 JP 2021545400 A JP2021545400 A JP 2021545400A JP 2021545400 A JP2021545400 A JP 2021545400A JP WO2020163365 A5 JPWO2020163365 A5 JP WO2020163365A5
- Authority
- JP
- Japan
- Prior art keywords
- zc3h12a
- socs1
- optionally
- immune effector
- targeting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Claims (34)
前記少なくとも2つの内在性遺伝子の前記発現及び/または前記機能の低下によって、前記免疫エフェクター細胞のエフェクター機能が増強される、前記改変免疫エフェクター細胞。 A modified immune effector cell comprising a gene regulatory system capable of reducing the expression and/or function of at least two endogenous target genes selected from SOCS1 , ZC3H12A and PTPN2 ,
Said modified immune effector cell, wherein said reduced expression and/or said reduced function of said at least two endogenous genes enhances the effector function of said immune effector cell.
必要に応じて、前記遺伝子調節システムが、siRNA、shRNA、マイクロRNA(miR)、アンタゴmiRまたはアンチセンスRNAから選択した核酸分子を含む;または
必要に応じて、前記遺伝子調節システムが、酵素タンパク質を含み、前記酵素タンパク質が、前記内在性遺伝子のうちの1つ以上における標的配列に特異的に結合するように操作されている;または
必要に応じて、前記タンパク質が、転写アクチベーター様エフェクターヌクレアーゼ(TALEN)、ジンクフィンガーヌクレアーゼまたはメガヌクレアーゼである、
請求項1または2に記載の改変免疫エフェクター細胞。 said gene regulatory system comprises (i) a nucleic acid molecule, (ii) an enzymatic protein or (iii) a nucleic acid molecule and an enzymatic protein;
optionally, said gene regulatory system comprises a nucleic acid molecule selected from siRNA, shRNA, microRNA (miR), antago-miR or antisense RNA; or
Optionally, said gene regulatory system comprises an enzymatic protein, said enzymatic protein engineered to specifically bind to a target sequence in one or more of said endogenous genes; or
optionally said protein is a transcriptional activator-like effector nuclease (TALEN), a zinc finger nuclease or a meganuclease ;
3. The modified immune effector cell of claim 1 or 2 .
必要に応じて、前記Casタンパク質が、Cas9タンパク質であり、必要に応じて、前記Casタンパク質が、酵素活性ドメインを2つ含み、二本鎖DNA切断を誘導することができる野生型Casタンパク質である;または
必要に応じて、前記Casタンパク質が、酵素活性ドメインを1つ含み、一本鎖DNA切断を誘導することができるCasニッカーゼ変異体である;または
必要に応じて、前記Casタンパク質が、不活性型Casタンパク質(dCas)であり、前記1つ以上の内在性標的遺伝子の発現を調節できる異種タンパク質と結合し、必要に応じて、前記異種タンパク質が、MAX相互作用タンパク質1(MXI1)、Kruppel関連ボックス(KRAB)ドメイン、メチル-CpG結合タンパク質2(MECP2)及びmSin3 4連結ドメイン(SID4X)からなる群から選択されている、
請求項3に記載の改変免疫エフェクター細胞。 said gene regulatory system comprises a nucleic acid molecule and an enzymatic protein, said nucleic acid molecule being a guide RNA (gRNA) molecule, said enzymatic protein being a Cas protein or a Cas orthologue;
Optionally, said Cas protein is a Cas9 protein, optionally said Cas protein is a wild-type Cas protein comprising two enzymatically active domains and capable of inducing double-stranded DNA breaks. ;or
Optionally, said Cas protein is a Cas nickase mutant that contains one enzymatically active domain and is capable of inducing single-stranded DNA breaks; or
Optionally, said Cas protein is an inactive Cas protein (dCas) and binds to a heterologous protein capable of regulating expression of said one or more endogenous target genes, optionally said heterologous protein is , MAX interacting protein 1 (MXI1), Kruppel-associated box (KRAB) domain, methyl-CpG binding protein 2 (MECP2) and mSin34-ligating domain (SID4X);
4. The modified immune effector cell of claim 3 .
前記少なくとも2つの内在性遺伝子が、SOCS1及びZC3H12Aであり、前記遺伝子調節システムが、前記SOCS1を標的とする少なくとも1つのgRNA分子であって、表3及び表4に示されている一連のゲノム座標のうちのいずれか1つによって定義される核酸配列に結合するターゲティングドメイン配列を含む前記gRNAと、前記ZC3H12Aを標的とする少なくとも1つのgRNA分子であって、表7及び表8に示されている一連のゲノム座標のうちのいずれか1つによって定義される核酸配列に結合するターゲティングドメイン配列を含む前記gRNAを含む;または
前記少なくとも2つの内在性遺伝子が、SOCS1及びZC3H12Aであり、前記遺伝子調節システムが、前記SOCS1を標的とする少なくとも1つのgRNA分子であって、配列番号7~151からなる群から選択した標的DNA配列に結合するターゲティングドメイン配列を含む前記gRNA分子と、前記ZC3H12Aを標的とする少なくとも1つのgRNA分子であって、配列番号208~230、配列番号376~812または配列番号376~575からなる群から選択した標的DNA配列に結合するターゲティングドメイン配列を含む前記gRNA分子を含む;または
前記少なくとも2つの内在性遺伝子が、SOCS1及びZC3H12Aであり、前記遺伝子調節システムが、前記SOCS1を標的とする少なくとも1つのgRNA分子であって、配列番号7~151からなる群から選択した核酸配列によってコードされるターゲティングドメイン配列を含む前記gRNA分子と、前記ZC3H12Aを標的とする少なくとも1つのgRNA分子であって、配列番号208~230、配列番号376~812または配列番号376~575からなる群から選択した核酸配列によってコードされるターゲティングドメイン配列を含む前記gRNA分子を含む、
請求項4に記載の改変免疫エフェクター細胞。 wherein said at least two endogenous genes are SOCS1 and ZC3H12A, said gene regulatory system is at least one gRNA molecule targeting said SOCS1, and a set of genomic coordinates shown in Tables 3 and 4. and at least one gRNA molecule targeting said ZC3H12A, shown in Tables 7 and 8. said gRNA molecule comprising a targeting domain sequence complementary to a nucleic acid sequence defined by any one of a set of genomic coordinates ; or
wherein said at least two endogenous genes are SOCS1 and ZC3H12A, said gene regulatory system is at least one gRNA molecule targeting said SOCS1, and a set of genomic coordinates shown in Tables 3 and 4. and at least one gRNA molecule targeting said ZC3H12A, shown in Tables 7 and 8. said gRNA comprising a targeting domain sequence that binds to a nucleic acid sequence defined by any one of a set of genomic coordinates; or
said at least two endogenous genes are SOCS1 and ZC3H12A, and said gene regulatory system is at least one gRNA molecule targeting said SOCS1, a target DNA sequence selected from the group consisting of SEQ ID NOS: 7-151. and at least one gRNA molecule targeting said ZC3H12A selected from the group consisting of SEQ ID NOs: 208-230, SEQ ID NOs: 376-812 or SEQ ID NOs: 376-575 said gRNA molecule comprising a targeting domain sequence that binds to a targeted DNA sequence; or
wherein said at least two endogenous genes are SOCS1 and ZC3H12A and said gene regulatory system is at least one gRNA molecule targeting said SOCS1 by a nucleic acid sequence selected from the group consisting of SEQ ID NOS: 7-151. said gRNA molecule comprising a targeting domain sequence encoded and at least one gRNA molecule targeting said ZC3H12A selected from the group consisting of SEQ ID NOs:208-230, SEQ ID NOs:376-812 or SEQ ID NOs:376-575 said gRNA molecule comprising a targeting domain sequence encoded by the nucleic acid sequence of
5. The modified immune effector cell of claim 4 .
前記少なくとも2つの内在性遺伝子が、SOCS1及びZC3H12Aであり、前記遺伝子調節システムが、前記SOCS1を標的とする少なくとも1つのsiRNA分子またはshRNA分子であって、表3及び表4に示されている一連のゲノム座標によって定義されるDNA配列によってコードされるRNA配列に結合する約19~30個のヌクレオチドを含む前記siRNA分子または前記shRNA分子と、前記ZC3H12Aを標的とする少なくとも1つのsiRNA分子またはshRNA分子であって、表7及び表8に示されている一連のゲノム座標によって定義されるDNA配列によってコードされるRNA配列に結合する約19~30個のヌクレオチドを含む前記siRNA分子または前記shRNA分子を含む;または
前記少なくとも2つの内在性遺伝子が、SOCS1及びZC3H12Aであり、前記遺伝子調節システムが、前記SOCS1を標的とする少なくとも1つのsiRNAまたはshRNAであって、配列番号7~151からなる群から選択したDNA配列によってコードされるRNA配列に結合する約19~30個のヌクレオチドを含む前記siRNAまたは前記shRNAと、前記ZC3H12Aを標的とする少なくとも1つのsiRNAまたはshRNAであって、配列番号208~230、配列番号376~812または配列番号376~575からなる群から選択したDNA配列によってコードされるRNA配列に結合する約19~30個のヌクレオチドを含む前記siRNAまたは前記shRNAを含む、
請求項3に記載の改変免疫エフェクター細胞。 wherein said at least two endogenous genes are SOCS1 and ZC3H12A and said gene regulatory system is at least one siRNA molecule or shRNA molecule targeting said SOCS1, wherein the sequences shown in Tables 3 and 4. said siRNA molecule or said shRNA molecule comprising about 19-30 nucleotides complementary to an RNA sequence encoded by a DNA sequence defined by the genomic coordinates of and at least one siRNA molecule targeting said ZC3H12A or an shRNA molecule comprising about 19-30 nucleotides complementary to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Tables 7 and 8; or comprising said shRNA molecule ; or
wherein said at least two endogenous genes are SOCS1 and ZC3H12A and said gene regulatory system is at least one siRNA molecule or shRNA molecule targeting said SOCS1, wherein the sequences shown in Tables 3 and 4. said siRNA or shRNA molecule comprising about 19-30 nucleotides that bind to an RNA sequence encoded by a DNA sequence defined by the genomic coordinates of and at least one siRNA or shRNA molecule that targets said ZC3H12A said siRNA molecule or said shRNA molecule comprising about 19-30 nucleotides that binds to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Tables 7 and 8 contains; or
said at least two endogenous genes are SOCS1 and ZC3H12A, said gene regulatory system is at least one siRNA or shRNA targeting said SOCS1, a DNA sequence selected from the group consisting of SEQ ID NOs: 7-151. and at least one siRNA or shRNA targeting said ZC3H12A, wherein SEQ ID NOs: 208-230, SEQ ID NO: 376 ~812 or said shRNA comprising about 19-30 nucleotides that bind to an RNA sequence encoded by a DNA sequence selected from the group consisting of SEQ ID NOs:376-575;
4. The modified immune effector cell of claim 3 .
前記少なくとも2つの内在性遺伝子が、SOCS1及びZC3H12Aであり、前記遺伝子調節システムが、前記SOCS1を標的とする少なくとも1つのTALEN、ジンクフィンガーまたはメガヌクレアーゼタンパク質であって、配列番号7~151から選択したDNA配列に結合する前記TALEN、前記ジンクフィンガーまたは前記メガヌクレアーゼタンパク質と、前記ZC3H12Aを標的とする少なくとも1つのTALEN、ジンクフィンガーまたはメガヌクレアーゼタンパク質であって、配列番号208~230、配列番号376~812または配列番号376~575から選択したDNA配列に結合する前記TALEN、前記ジンクフィンガーまたは前記メガヌクレアーゼタンパク質を含む、
請求項3に記載の改変免疫エフェクター細胞。 wherein said at least two endogenous genes are SOCS1 and ZC3H12A and said gene regulatory system is at least one TALEN, zinc finger or meganuclease protein targeting said SOCS1, shown in Tables 3 and 4. said TALEN, said zinc finger or said meganuclease protein that binds to a target DNA sequence defined by a set of genomic coordinates, and at least one TALEN, zinc finger or meganuclease protein that targets said ZC3H12A, said TALEN, said zinc finger or said meganuclease protein that binds to a target DNA sequence defined by a set of genomic coordinates shown in Tables 7 and 8 ; or
said at least two endogenous genes are SOCS1 and ZC3H12A, and said gene regulatory system is at least one TALEN, zinc finger or meganuclease protein targeting said SOCS1, selected from SEQ ID NOs: 7-151 said TALEN, said zinc finger or said meganuclease protein that binds to a DNA sequence and at least one TALEN, zinc finger or meganuclease protein that targets said ZC3H12A, comprising: SEQ ID NOs: 208-230; SEQ ID NOs: 376-812 or said TALEN, said zinc finger or said meganuclease protein that binds to a DNA sequence selected from SEQ ID NOS: 376-575;
4. The modified immune effector cell of claim 3 .
必要に応じて、前記SOCS1を標的とする少なくとも1つのgRNA分子が、表3及び表4に示されている一連のゲノム座標によって定義される核酸配列と相補的なターゲティングドメイン配列を含み、前記ZC3H12Aを標的とする少なくとも1つのgRNA分子が、表7及び表8に示されている一連のゲノム座標によって定義される核酸配列と相補的なターゲティングドメイン配列を含む;または
必要に応じて、前記SOCS1を標的とする少なくとも1つのgRNA分子が、表3及び表4に示されている一連のゲノム座標によって定義される核酸配列に結合するターゲティングドメイン配列を含み、前記ZC3H12Aを標的とする少なくとも1つのgRNA分子が、表7及び表8に示されている一連のゲノム座標によって定義される核酸配列に結合するターゲティングドメイン配列を含む;または
前記SOCS1を標的とする少なくとも1つのgRNA分子が、配列番号7~151から選択した標的DNA配列に結合するターゲティングドメイン配列を含み、前記ZC3H12Aを標的とする少なくとも1つのgRNA分子が、配列番号208~230、配列番号376~812または配列番号376~575から選択した標的DNA配列に結合するターゲティングドメイン配列を含む;または
前記SOCS1を標的とする少なくとも1つのgRNA分子が、配列番号7~151から選択した核酸配列によってコードされるターゲティングドメイン配列を含み、前記ZC3H12Aを標的とする少なくとも1つのgRNA分子が、配列番号208~230、配列番号376~812または配列番号376~575から選択した核酸配列によってコードされるターゲティングドメイン配列を含む、
請求項20に記載の遺伝子調節システム。 comprising at least two guide RNA (gRNA) nucleic acid molecules and a Cas endonuclease, optionally said system comprises at least one gRNA molecule targeting said SOCS1, at least one gRNA molecule targeting said ZC3H12A , and a Cas endonuclease;
Optionally, said at least one gRNA molecule targeting SOCS1 comprises a targeting domain sequence complementary to a nucleic acid sequence defined by a set of genomic coordinates shown in Tables 3 and 4, wherein said ZC3H12A at least one gRNA molecule targeting comprises a targeting domain sequence complementary to a nucleic acid sequence defined by a set of genomic coordinates shown in Tables 7 and 8; or
Optionally, said at least one gRNA molecule targeting SOCS1 comprises a targeting domain sequence that binds to a nucleic acid sequence defined by a set of genomic coordinates shown in Tables 3 and 4, wherein said ZC3H12A is at least one targeted gRNA molecule comprises a targeting domain sequence that binds to a nucleic acid sequence defined by a set of genomic coordinates shown in Tables 7 and 8; or
said at least one gRNA molecule targeting SOCS1 comprises a targeting domain sequence that binds to a target DNA sequence selected from SEQ ID NOS:7-151; 230, SEQ ID NOS: 376-812 or SEQ ID NOS: 376-575, comprising a targeting domain sequence that binds to a target DNA sequence; or
said at least one gRNA molecule targeting SOCS1 comprises a targeting domain sequence encoded by a nucleic acid sequence selected from SEQ ID NOS: 7-151, and said at least one gRNA molecule targeting ZC3H12A comprises 230, SEQ ID NOs:376-812 or SEQ ID NOs:376-575, comprising a targeting domain sequence encoded by a nucleic acid sequence selected from
21. The gene regulatory system of claim 20 .
必要に応じて、前記Casタンパク質が、酵素活性ドメインを2つ含むとともに、二本鎖DNA切断を誘導することができる野生型Casタンパク質である;または
必要に応じて、前記Casタンパク質が、酵素活性ドメインを1つ含むとともに、一本鎖DNA切断を誘導することができるCasニッカーゼ変異体である;または
必要に応じて、前記Casタンパク質が、不活性型Casタンパク質(dCas)であり、前記1つ以上の内在性標的遺伝子の発現を調節できる異種タンパク質と結合し、必要に応じて、前記異種タンパク質が、MAX相互作用タンパク質1(MXI1)、Kruppel関連ボックス(KRAB)ドメイン及びmSin3 4連結ドメイン(SID4X)からなる群から選択されている、
請求項21に記載の遺伝子調節システム。 the Cas protein is a Cas9 protein,
Optionally, said Cas protein is a wild-type Cas protein that contains two enzymatically active domains and is capable of inducing double-stranded DNA breaks; or
Optionally, said Cas protein is a Cas nickase mutant containing one enzymatically active domain and capable of inducing single-stranded DNA breaks; or
Optionally, said Cas protein is an inactive Cas protein (dCas) and binds to a heterologous protein capable of regulating expression of said one or more endogenous target genes, optionally said heterologous protein is , MAX interacting protein 1 (MXI1), Kruppel-associated box (KRAB) domain and mSin34-linked domain (SID4X);
22. The gene regulatory system of claim 21 .
必要に応じて、前記SOCS1を標的とする少なくとも1つのsiRNA分子またはshRNA分子が、表3及び表4に示されている一連のゲノム座標によって定義されるDNA配列によってコードされるRNA配列と相補的である約19~30個のヌクレオチドを含み、前記ZC3H12Aを標的とする少なくとも1つのsiRNA分子またはshRNA分子が、表7及び表8に示されている一連のゲノム座標によって定義されるDNA配列によってコードされるRNA配列と相補的である約19~30個のヌクレオチドを含む;または
必要に応じて、前記SOCS1を標的とする少なくとも1つのsiRNA分子またはshRNA分子が、表3及び表4に示されている一連のゲノム座標によって定義されるDNA配列によってコードされるRNA配列に結合する約19~30個のヌクレオチドを含み、前記ZC3H12Aを標的とする少なくとも1つのsiRNA分子またはshRNA分子が、約19~30個のヌクレオチドを含み、表7及び表8に示されている一連のゲノム座標によって定義されるDNA配列によってコードされるRNA配列に結合する;または
必要に応じて、前記SOCS1を標的とする少なくとも1つのsiRNAまたはshRNAが、配列番号7~151から選択したDNA配列によってコードされるRNA配列に結合する約19~30個のヌクレオチドを含み、前記ZC3H12Aを標的とする少なくとも1つのsiRNAまたはshRNAが、配列番号208~230、配列番号376~812または配列番号376~575から選択したDNA配列によってコードされるRNA配列に結合する約19~30個のヌクレオチドを含む、
請求項20に記載の遺伝子調節システム。 Said system comprises at least two nucleic acid molecules, wherein said at least two nucleic acid molecules are selected from siRNA, shRNA, microRNA (miR), antago-miR or antisense RNA ; optionally said system comprises SOCS1 and at least one siRNA or shRNA molecule that targets ZC3H12A;
Optionally, said at least one siRNA or shRNA molecule targeting SOCS1 is complementary to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Tables 3 and 4. at least one siRNA or shRNA molecule targeting said ZC3H12A comprising about 19-30 nucleotides of is encoded by a DNA sequence defined by a set of genomic coordinates shown in Tables 7 and 8 contains about 19-30 nucleotides that are complementary to the RNA sequence of the target; or
Optionally, said at least one siRNA or shRNA molecule targeting SOCS1 binds to an RNA sequence encoded by a DNA sequence defined by a set of genomic coordinates shown in Tables 3 and 4. wherein said at least one siRNA or shRNA molecule targeting ZC3H12A comprises about 19-30 nucleotides, wherein said set of genomic coordinates comprises about 19-30 nucleotides and is shown in Tables 7 and 8; binds to an RNA sequence encoded by a DNA sequence defined by; or
Optionally, said at least one siRNA or shRNA targeting SOCS1 comprises about 19-30 nucleotides that bind to an RNA sequence encoded by a DNA sequence selected from SEQ ID NOS: 7-151, and said ZC3H12A about 19-30 nucleotides that bind to an RNA sequence encoded by a DNA sequence selected from SEQ ID NOs: 208-230, SEQ ID NOs: 376-812, or SEQ ID NOs: 376-575 including
21. The gene regulatory system of claim 20 .
前記第1の標的遺伝子が、SOCS1であり、前記SOCS1を標的とする少なくとも1つのgRNAが、配列番号7~151から選択した核酸配列によってコードされるターゲティングドメイン配列を含み、
前記第2の標的遺伝子が、ZC3H12Aであり、前記ZC3H12Aを標的とする少なくとも1つのgRNAが、配列番号208~230、配列番号376~812または配列番号376~575から選択した核酸配列によってコードされるターゲティングドメイン配列を含む、
請求項20~22のいずれか1項に記載の遺伝子調節システム。 said gene regulation system comprising at least one gRNA targeting a first target gene, at least one gRNA targeting a second target gene, and one or more vectors encoding a Cas endonuclease protein;
said first target gene is SOCS1 and said at least one gRNA targeting SOCS1 comprises a targeting domain sequence encoded by a nucleic acid sequence selected from SEQ ID NOs: 7-151;
said second target gene is ZC3H12A, and at least one gRNA targeting said ZC3H12A is encoded by a nucleic acid sequence selected from SEQ ID NOs: 208-230, SEQ ID NOs: 376-812 or SEQ ID NOs: 376-575 containing a targeting domain sequence,
Gene regulatory system according to any one of claims 20-22 .
遺伝子調節システムを免疫エフェクター細胞に導入することであって、前記遺伝子調節システムが、SOCS1、ZC3H12A及びPTPN2から選択した少なくとも2つの内在性標的遺伝子の発現及び/または機能を低下させることができる前記導入することであって、前記遺伝子調節システムが、請求項20~25のいずれか1項から選択した遺伝子調節システムであり、必要に応じて、CAR及びTCRから選択した操作免疫受容体をコードするポリヌクレオチド配列を導入することをさらに含む;または
免疫エフェクター細胞における少なくとも2つの内在性標的遺伝子に不活性化変異を導入することであって、前記少なくとも2つの内在性標的遺伝子が、SOCS1、ZC3H12A及びPTPN2から選択される前記導入することを含む;または
免疫エフェクター細胞における少なくとも2つの内在性標的遺伝子の核酸阻害剤を少なくとも2つコードする1つ以上の外因性ポリヌクレオチドを導入することであって、前記少なくとも2つの内在性標的遺伝子が、SOCS1、ZC3H12A及びPTPN2から選択される前記導入することを含む、
前記方法。 A method of producing an engineered immune effector cell comprising:
introducing a gene regulatory system into the immune effector cells, said introduction being capable of reducing the expression and/or function of at least two endogenous target genes selected from SOCS1 , ZC3H12A and PTPN2 . wherein said gene regulatory system is a gene regulatory system selected from any one of claims 20 to 25, and optionally a polyisocyanate encoding an engineered immune receptor selected from CAR and TCR. further comprising introducing a nucleotide sequence; or
introducing inactivating mutations into at least two endogenous target genes in immune effector cells, wherein said at least two endogenous target genes are selected from SOCS1, ZC3H12A and PTPN2; or
introducing one or more exogenous polynucleotides encoding at least two nucleic acid inhibitors of at least two endogenous target genes in immune effector cells, wherein said at least two endogenous target genes are SOCS1, ZC3H12A and PTPN2.
the aforementioned method.
必要に応じて、前記疾患または障害が、細胞増殖性障害、炎症性障害または感染症である;または
必要に応じて、前記疾患または障害が、がんまたはウイルス感染症であり、必要に応じて、前記がんが、白血病、リンパ腫または固形腫瘍から選択され、必要に応じて、前記固形腫瘍が、メラノーマ、膵臓腫瘍、膀胱腫瘍、または肺腫瘍もしくは肺転移であり、必要に応じて、前記がんが、PD1耐性またはPD1非感受性のがんであり、必要に応じて、前記対象が以前に、PD1阻害剤またはPDL1阻害剤による治療を受けたことがある、
組成物。 A composition comprising the modified immune effector cells of any one of claims 1 to 18 or a composition of claim 19 for the treatment of a disease or disorder of a subject in need thereof, ,
optionally said disease or disorder is a cell proliferative disorder, an inflammatory disorder or an infectious disease; or
Optionally, said disease or disorder is cancer or viral infection, optionally said cancer is selected from leukemia, lymphoma or solid tumor, optionally said solid tumor is melanoma, pancreatic tumor, bladder tumor, or lung tumor or lung metastasis, optionally said cancer is a PD1-resistant or PD1-insensitive cancer, optionally said subject has previously had PD1 have been treated with inhibitors or PDL1 inhibitors,
composition .
請求項1~18のいずれか1項に記載の改変免疫エフェクター細胞を含む組成物、または請求項19に記載の組成物であって、前記方法が、前記がん細胞を前記組成物に暴露することを含み、
前記改変免疫エフェクター細胞に暴露すると、改変していない免疫エフェクター細胞に暴露する場合と比べて、前記がん細胞の殺傷性が増大し、必要に応じて、前記暴露が、in vitro、in vivoまたはex vivoでの暴露である、前記組成物。 for use in methods of killing cancer cells,
A composition comprising the modified immune effector cells of any one of claims 1-18 , or a composition of claim 19 , wherein said method comprises exposing said cancer cells to said composition including doing
Exposure to said modified immune effector cells increases killing of said cancer cells compared to exposure to unmodified immune effector cells, and optionally said exposure is in vitro, in vivo or The composition, which is an ex vivo exposure .
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962800999P | 2019-02-04 | 2019-02-04 | |
US62/800,999 | 2019-02-04 | ||
US201962818677P | 2019-03-14 | 2019-03-14 | |
US62/818,677 | 2019-03-14 | ||
PCT/US2020/016623 WO2020163365A2 (en) | 2019-02-04 | 2020-02-04 | Combination gene targets for improved immunotherapy |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022519595A JP2022519595A (en) | 2022-03-24 |
JPWO2020163365A5 true JPWO2020163365A5 (en) | 2023-02-10 |
Family
ID=71947815
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021545400A Pending JP2022519595A (en) | 2019-02-04 | 2020-02-04 | Combination of gene targets for improved immunotherapy |
Country Status (12)
Country | Link |
---|---|
US (1) | US20200347386A1 (en) |
EP (1) | EP3920942A4 (en) |
JP (1) | JP2022519595A (en) |
KR (1) | KR20210138587A (en) |
CN (1) | CN113396216A (en) |
AU (1) | AU2020217715A1 (en) |
BR (1) | BR112021015170A2 (en) |
CA (1) | CA3128823A1 (en) |
IL (1) | IL285307A (en) |
MX (1) | MX2021009357A (en) |
SG (1) | SG11202108452WA (en) |
WO (1) | WO2020163365A2 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3765094A4 (en) | 2018-03-15 | 2021-12-22 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
KR20230056766A (en) * | 2020-08-28 | 2023-04-27 | 제넨테크, 인크. | CRISPR/Cas9 multiple knockout of host cell proteins |
US20240060091A1 (en) * | 2020-12-17 | 2024-02-22 | University of Florida Research Foundation, Incorporation | Method for programmable control of rna transcript levels with autoregulated crispr-cas13d |
US20220288122A1 (en) * | 2021-03-09 | 2022-09-15 | Crispr Therapeutics Ag | Genetically engineered t cells with ptpn2 knockout have improved functionality and anti-tumor activity |
WO2023015213A1 (en) * | 2021-08-03 | 2023-02-09 | Spotlight Therapeutics | Ptpn2 specific guide rnas and uses thereof |
WO2023082640A1 (en) * | 2021-11-10 | 2023-05-19 | 清华大学 | Method for enhancing durability of immune cell |
WO2023096928A1 (en) * | 2021-11-23 | 2023-06-01 | Kumquat Biosciences Inc. | Hetero-atom containing compounds and uses thereof |
WO2023131053A1 (en) * | 2022-01-05 | 2023-07-13 | 苏州系统医学研究所 | T cell receptor, and preparation method therefor and use thereof |
WO2023143515A1 (en) * | 2022-01-29 | 2023-08-03 | 苏州沙砾生物科技有限公司 | Modified tumor infiltrating lymphocyte and use thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7348139B1 (en) * | 2001-04-13 | 2008-03-25 | The Johns Hopkins University School Of Medicine | SOCS-1 gene methylation in cancer |
US20130331294A1 (en) * | 2007-11-09 | 2013-12-12 | Fox Chase Cancer Center | Egfr/nedd9/tgf-beta interactome and methods of use thereof for the identification of agents having efficacy in the treatment of hyperproliferative disorders |
WO2010098429A1 (en) * | 2009-02-27 | 2010-09-02 | 国立大学法人大阪大学 | Immunologic adjuvant composition and use thereof |
US20150017136A1 (en) * | 2013-07-15 | 2015-01-15 | Cellectis | Methods for engineering allogeneic and highly active t cell for immunotherapy |
CN111218447A (en) * | 2013-11-07 | 2020-06-02 | 爱迪塔斯医药有限公司 | CRISPR-associated methods and compositions using dominant grnas |
WO2018148378A1 (en) * | 2017-02-08 | 2018-08-16 | Dana-Farber Cancer Institute, Inc. | Modulating biomarkers to increase tumor immunity and improve the efficiacy of cancer immunotherapy |
AU2019236205A1 (en) * | 2018-03-15 | 2020-10-08 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
-
2020
- 2020-02-04 SG SG11202108452WA patent/SG11202108452WA/en unknown
- 2020-02-04 US US16/781,732 patent/US20200347386A1/en active Pending
- 2020-02-04 AU AU2020217715A patent/AU2020217715A1/en active Pending
- 2020-02-04 WO PCT/US2020/016623 patent/WO2020163365A2/en active Search and Examination
- 2020-02-04 CA CA3128823A patent/CA3128823A1/en active Pending
- 2020-02-04 CN CN202080012560.2A patent/CN113396216A/en active Pending
- 2020-02-04 BR BR112021015170-2A patent/BR112021015170A2/en unknown
- 2020-02-04 MX MX2021009357A patent/MX2021009357A/en unknown
- 2020-02-04 KR KR1020217028228A patent/KR20210138587A/en unknown
- 2020-02-04 EP EP20751889.5A patent/EP3920942A4/en active Pending
- 2020-02-04 JP JP2021545400A patent/JP2022519595A/en active Pending
-
2021
- 2021-08-02 IL IL285307A patent/IL285307A/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2021164463A (en) | Compositions and methods for epigenome editing | |
Bernstein et al. | TALE-mediated epigenetic suppression of CDKN2A increases replication in human fibroblasts | |
JP2021534810A (en) | Methods and Compositions for Editing RNA | |
Lawrie | Micro RNA s and lymphomagenesis: a functional review | |
Soldevilla et al. | 2-fluoro-RNA oligonucleotide CD40 targeted aptamers for the control of B lymphoma and bone-marrow aplasia | |
JP2022526455A (en) | Methods and Compositions for Editing RNA | |
JPWO2019178422A5 (en) | ||
CN116322716A (en) | Genetically engineered T cells disrupted by Regnase-1 and/or TGFBRII have improved functionality and persistence | |
JP2017513520A (en) | Production of genetically modified T cells with Sleeping Beauty transposon combined with selection with methotrexate | |
US20220169984A1 (en) | Improved process for dna integration using rna-guided endonucleases | |
US20220145333A1 (en) | Improved process for integration of dna constructs using rna-guided endonucleases | |
JP2021502077A5 (en) | ||
JP2022513586A (en) | Anti-LIV1 immune cell cancer therapy | |
JPWO2020163365A5 (en) | ||
JP2022519070A (en) | Gene regulation compositions and methods for improving immunotherapy | |
JP2022509017A (en) | Anti-PTK7 immune cell cancer therapy | |
CN108495640B (en) | Short hairpin RNA (SHRNA 734) and its use for positive selection and elimination of genetically modified cells | |
WO2022261115A1 (en) | Peptide nucleic acids for spatiotemporal control of crispr-cas binding | |
WO2022012531A1 (en) | Method for preparing modified immune cell | |
JPWO2019178420A5 (en) | ||
JPWO2019178421A5 (en) | ||
JPWO2021136263A5 (en) | ||
WO2022015956A1 (en) | Improved process for dna integration using rna-guided endonucleases | |
JPWO2020176740A5 (en) | ||
CN112823209A (en) | Methods of treating diseases using nucleic acid vectors encoding highly compact multiple input logic gates |